From February 27 to March 1, 2019, Tel Aviv (Israel) passed the course "Where the Medical and Radiation Oncology Meet: Integrative State of the Art Strategies" in which the Associate Professor of the Oncology Department of the Shupyk NMAPE PhD, MD Olga Ponomarova and post-graduate student of the Oncology Department of Shupyk NMAPE Anastasiia Samusieva have participated.
The course was organized by the European School of Oncology (ESO) and was devoted to the latest developments in local and systemic personalized management of the breast cancer, gastrointestinal cancer, lung cancer and head & neck cancer. The lectures were given by faculty, consisted of the leading European and Israeli specialists in the field of oncology, who focused their attention on updating of knowledge in local and systemic personalized management for breast cancer, gastrointestinal cancer, lung cancer and head & neck cancer, as well as innovative strategies in a combined modality therapy of the above mentioned malignancies and the methods of the innovative strategies introduction in medicinal therapy and precision radiotherapy in everyday practice. The latest meta-analysis and current reviews were presented, as well as the results of the third phase clinical trials and the potential directions of future research.
Within the course nearly 40 papers were presented and Emmanuel Van Der Schueren Award was given.
24 doctors from other countries were registered for this course, among them almost half were oncologists and radiologists from Ukraine. Many actual problems were discussed about the treatment of not only patients with early cancer, but concerning the algorithms and tactics for the management of patients with metastases. A great deal of attention was paid to the role of genetic mutations and immunotherapy. Also valuable were the materials of clinical cases, which allowed to assess the impact of different tactics of treatment on the course of the disease.
The course greatly contributed to the creation of a platform for solving of common issues among clinical oncologists, oncology surgeons and radiologists, with regard to the choice of optimal treatment strategy and tactics.